IL302336B2 - Methods of treating liver disorders or lipid disorders with a thr-beta agonist - Google Patents
Methods of treating liver disorders or lipid disorders with a thr-beta agonistInfo
- Publication number
- IL302336B2 IL302336B2 IL302336A IL30233623A IL302336B2 IL 302336 B2 IL302336 B2 IL 302336B2 IL 302336 A IL302336 A IL 302336A IL 30233623 A IL30233623 A IL 30233623A IL 302336 B2 IL302336 B2 IL 302336B2
- Authority
- IL
- Israel
- Prior art keywords
- compound
- subject
- dose
- test
- biomarker
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409833P | 2016-10-18 | 2016-10-18 | |
| US201762516594P | 2017-06-07 | 2017-06-07 | |
| PCT/US2017/057203 WO2018075650A1 (en) | 2016-10-18 | 2017-10-18 | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL302336A IL302336A (en) | 2023-06-01 |
| IL302336B1 IL302336B1 (en) | 2025-07-01 |
| IL302336B2 true IL302336B2 (en) | 2025-11-01 |
Family
ID=60480362
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL302336A IL302336B2 (en) | 2016-10-18 | 2017-10-18 | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
| IL266054A IL266054B2 (en) | 2016-10-18 | 2017-10-18 | Methods for treating liver disorders or lipid disorders using a THR-BETA agonist |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL266054A IL266054B2 (en) | 2016-10-18 | 2017-10-18 | Methods for treating liver disorders or lipid disorders using a THR-BETA agonist |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11090308B2 (https=) |
| EP (2) | EP3528817B1 (https=) |
| JP (3) | JP2019533019A (https=) |
| KR (2) | KR20230156159A (https=) |
| CN (1) | CN110167557A (https=) |
| AU (1) | AU2017346871B2 (https=) |
| CA (1) | CA3040888A1 (https=) |
| DK (1) | DK3528817T3 (https=) |
| ES (1) | ES2924257T3 (https=) |
| IL (2) | IL302336B2 (https=) |
| MX (1) | MX394463B (https=) |
| WO (1) | WO2018075650A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR092872A1 (es) | 2012-09-17 | 2015-05-06 | Madrigal Pharmaceuticals Inc | Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos |
| NZ748641A (en) | 2016-06-13 | 2020-04-24 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| WO2018075650A1 (en) | 2016-10-18 | 2018-04-26 | Madrigal Pharmaceuticals, Inc. | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
| SI4122464T1 (sl) | 2017-03-28 | 2024-07-31 | Gilead Sciences, Inc. | Terapevtske kombinacije za zdravljenje bolezni jeter |
| ES3029158T3 (en) | 2018-06-12 | 2025-06-23 | Xizang Haisco Pharmaceutical Co Ltd | Thyroid hormone receptor agonists and uses thereof |
| CN110627773B (zh) * | 2018-06-22 | 2021-03-19 | 海创药业股份有限公司 | 氘代mgl-3196化合物及其用途 |
| AR115666A1 (es) * | 2018-07-02 | 2021-02-10 | Madrigal Pharmaceuticals Inc | Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo |
| CA3111025C (en) * | 2018-09-06 | 2023-10-31 | Galmed Research And Development Ltd | Combination therapy for the treatment of liver disease |
| TWI884745B (zh) | 2018-10-12 | 2025-05-21 | 美商拓臻股份有限公司 | 甲狀腺素受體β促效劑化合物 |
| CN111320609A (zh) * | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| PT3911647T (pt) * | 2019-01-15 | 2024-03-04 | Gilead Sciences Inc | Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham |
| JP2022519906A (ja) | 2019-02-19 | 2022-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｘｒアゴニストの固体形態 |
| CN113474335B (zh) * | 2019-02-21 | 2024-12-03 | 南京瑞捷医药科技有限公司 | 化合物及其作为甲状腺激素受体激动剂的用途 |
| KR20220017917A (ko) | 2019-05-08 | 2022-02-14 | 알리고스 테라퓨틱스 인코포레이티드 | Thr-베타의 조절제 및 이의 사용 방법 |
| AU2020336272A1 (en) * | 2019-08-23 | 2022-04-14 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021050945A1 (en) * | 2019-09-12 | 2021-03-18 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021063367A1 (zh) * | 2019-09-30 | 2021-04-08 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| WO2021104288A1 (zh) * | 2019-11-26 | 2021-06-03 | 昆药集团股份有限公司 | 1，2，4-三嗪-3，5-二酮类化合物及其制备方法和应用 |
| CN111562321B (zh) * | 2020-04-16 | 2022-10-28 | 广东省结核病控制中心 | 用于检测活动性肺结核的粪便代谢物及其检测系统 |
| WO2022052822A1 (zh) * | 2020-09-10 | 2022-03-17 | 苏州科睿思制药有限公司 | Resmetirom的晶型及其制备方法和用途 |
| EP4204419A1 (en) | 2020-10-19 | 2023-07-05 | Teva Pharmaceuticals International GmbH | Solid state forms of resmetirom |
| KR20230142523A (ko) * | 2021-02-01 | 2023-10-11 | 마드리갈 파마슈티칼스, 인크. | 간 장애 또는 지질 장애의 치료를 위한 로수바스타틴 및 레스메티롬의 치료용 조합 |
| US20250000836A1 (en) * | 2021-07-21 | 2025-01-02 | Cyta Therapeutics, Inc. | Particle delivery of thyroid hormone receptor agonists and antagonists |
| PE20241327A1 (es) * | 2021-11-11 | 2024-06-26 | Terns Pharmaceuticals Inc | Tratamiento de trastornos hepaticos con un agonista del thr-beta |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| WO2024263714A1 (en) * | 2023-06-22 | 2024-12-26 | Madrigal Pharmaceuticals, Inc. | BIOMARKERS FOR TREATING LIVER DISORDERS WITH THR-β AGONISTS AND RELATED USES |
| WO2025011259A1 (zh) * | 2023-07-07 | 2025-01-16 | 苏州科睿思制药有限公司 | 瑞司美替罗的晶型及其制备方法和用途 |
| WO2025083699A2 (en) | 2023-10-16 | 2025-04-24 | Cipla Limited | Resmetirom polymorphs and process thereof |
| US12377104B1 (en) | 2024-02-06 | 2025-08-05 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| WO2025245216A1 (en) * | 2024-05-22 | 2025-11-27 | Terns Pharmaceuticals, Inc. | Treatment of liver disorders with a thr-beta agonist |
| WO2026074443A1 (en) | 2024-10-01 | 2026-04-09 | Assia Chemical Industries Ltd. | Solid state forms of resmetirom |
| CN121648128A (zh) * | 2026-02-03 | 2026-03-13 | 华中科技大学同济医学院附属同济医院 | 特拉唑嗪或其药学上可接受的盐在制备用于预防和/或治疗肝纤维化的药物中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150203473A1 (en) * | 2012-09-17 | 2015-07-23 | Madrigal Pharmaceuticals, Inc. | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5615272A (en) | 1979-07-17 | 1981-02-14 | Ishihara Sangyo Kaisha Ltd | N-benzoyl-n'-phenylurea compound, its preparation, and insecticide containing the same |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| CN100469769C (zh) | 2003-03-24 | 2009-03-18 | 弗·哈夫曼-拉罗切有限公司 | 作为逆转录酶抑制剂的苄基-哒嗪酮 |
| ITRM20030363A1 (it) | 2003-07-24 | 2005-01-25 | Fernando Goglia | Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse. |
| US20080152700A1 (en) | 2004-06-01 | 2008-06-26 | Reza Sheikhnejad | Methods and compositions for the inhibition of gene expression |
| US7807647B2 (en) | 2004-06-01 | 2010-10-05 | Pronai Therapeutics, Inc. | Methods and compositions for cancer therapy |
| DK1919878T3 (da) | 2005-07-21 | 2010-10-25 | Hoffmann La Roche | Pyridazinonderivater som thyroidhormonreceptoragonister |
| HRP20100611T1 (hr) | 2007-06-06 | 2010-12-31 | Torrent Pharmaceuticals Ltd | Novi spojevi |
| US8076334B2 (en) | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
| US8858502B2 (en) | 2012-10-10 | 2014-10-14 | Alcon Research, Ltd. | Systems and methods for external pressure sensing |
| CN106132969A (zh) * | 2014-02-14 | 2016-11-16 | 森普拉制药公司 | 用于治疗糖尿病和肝病的组合物和方法 |
| WO2018075650A1 (en) | 2016-10-18 | 2018-04-26 | Madrigal Pharmaceuticals, Inc. | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
| AR115666A1 (es) | 2018-07-02 | 2021-02-10 | Madrigal Pharmaceuticals Inc | Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo |
-
2017
- 2017-10-18 WO PCT/US2017/057203 patent/WO2018075650A1/en not_active Ceased
- 2017-10-18 JP JP2019542355A patent/JP2019533019A/ja active Pending
- 2017-10-18 EP EP17804979.7A patent/EP3528817B1/en active Active
- 2017-10-18 IL IL302336A patent/IL302336B2/en unknown
- 2017-10-18 MX MX2019004492A patent/MX394463B/es unknown
- 2017-10-18 US US16/343,065 patent/US11090308B2/en active Active
- 2017-10-18 EP EP22175048.2A patent/EP4112056B1/en active Active
- 2017-10-18 IL IL266054A patent/IL266054B2/en unknown
- 2017-10-18 KR KR1020237037485A patent/KR20230156159A/ko active Pending
- 2017-10-18 CA CA3040888A patent/CA3040888A1/en active Pending
- 2017-10-18 AU AU2017346871A patent/AU2017346871B2/en active Active
- 2017-10-18 CN CN201780078133.2A patent/CN110167557A/zh active Pending
- 2017-10-18 KR KR1020197014495A patent/KR20190109387A/ko not_active Ceased
- 2017-10-18 ES ES17804979T patent/ES2924257T3/es active Active
- 2017-10-18 DK DK17804979.7T patent/DK3528817T3/da active
-
2021
- 2021-07-07 US US17/369,197 patent/US11806353B2/en active Active
-
2023
- 2023-09-21 US US18/371,229 patent/US20240156826A1/en not_active Abandoned
- 2023-09-22 JP JP2023157999A patent/JP2024001055A/ja active Pending
-
2025
- 2025-05-12 JP JP2025079296A patent/JP2025122012A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150203473A1 (en) * | 2012-09-17 | 2015-07-23 | Madrigal Pharmaceuticals, Inc. | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Non-Patent Citations (1)
| Title |
|---|
| AUB REBECCA ET AL,, LIPID LOWERING IN HEALTHY VOLUNTEERS TREATED WITH MULTIPLE DOSES OF MGL-3196, A LIVER-TARGETED THYROID HORMONE RECEPTOR-[BETA] AGO, 21 August 2013 (2013-08-21) * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL302336A (en) | 2023-06-01 |
| MX394463B (es) | 2025-03-19 |
| JP2025122012A (ja) | 2025-08-20 |
| AU2017346871B2 (en) | 2023-08-03 |
| CA3040888A1 (en) | 2018-04-26 |
| JP2024001055A (ja) | 2024-01-09 |
| DK3528817T3 (da) | 2022-08-08 |
| IL266054A (en) | 2019-06-30 |
| EP4112056A1 (en) | 2023-01-04 |
| AU2017346871A1 (en) | 2019-05-02 |
| EP3528817A1 (en) | 2019-08-28 |
| IL266054B2 (en) | 2023-10-01 |
| MX2019004492A (es) | 2019-11-18 |
| US20210330675A1 (en) | 2021-10-28 |
| KR20230156159A (ko) | 2023-11-13 |
| CN110167557A (zh) | 2019-08-23 |
| IL302336B1 (en) | 2025-07-01 |
| JP2019533019A (ja) | 2019-11-14 |
| ES2924257T3 (es) | 2022-10-05 |
| US11090308B2 (en) | 2021-08-17 |
| EP4112056B1 (en) | 2026-01-21 |
| US20240156826A1 (en) | 2024-05-16 |
| KR20190109387A (ko) | 2019-09-25 |
| WO2018075650A1 (en) | 2018-04-26 |
| IL266054B1 (en) | 2023-06-01 |
| US20200230146A1 (en) | 2020-07-23 |
| US11806353B2 (en) | 2023-11-07 |
| EP3528817B1 (en) | 2022-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11806353B2 (en) | Methods of treating liver disorders or lipid disorders with a THR-beta agonist | |
| US20200339591A1 (en) | Compositions and methods of treatment for neurological disorders comprising a dementia | |
| US20200325148A1 (en) | Compositions and methods of treatment for neurological disorders comprising motor neuron diseases | |
| EA021731B1 (ru) | Новые композиции для лечения болезни альцгеймера | |
| JP2019533019A5 (https=) | ||
| KR20090038908A (ko) | 대사 장애의 조합 치료 | |
| EA036404B1 (ru) | Фармацевтические композиции для комбинированной терапии | |
| EP3661500B1 (en) | Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use | |
| JP2015522080A (ja) | スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物 | |
| US20180344694A1 (en) | Use of indole compounds to stimulate the immune system | |
| US20230100247A1 (en) | Taxol conjugate compounds, pharmaceutical compositions comprising the same, and methods for their use | |
| US20150099270A1 (en) | Method of screening pharmaceuticals for drug interactions and nephrotoxicity | |
| Xu et al. | E17241 as a novel ABCA1 (ATP-binding cassette transporter A1) upregulator ameliorates atherosclerosis in mice | |
| US20190008878A1 (en) | Compositions and method for reducing cardiotoxicity | |
| US20200069697A1 (en) | Treatment of cancer and inhibition of metastasis | |
| US11517581B2 (en) | Zika virus protease inhibitors and methods of use thereof | |
| CN116271033B (zh) | 一种以sqle基因或蛋白为靶点治疗克唑替尼肝脏毒性的药物 | |
| EP4051273A1 (en) | Treatment of renal cystic disease | |
| US20250288572A1 (en) | Compositions and methods for treating pulmonary vascular disease | |
| EP3344244A1 (en) | Use of indole compounds to stimulate the immune system | |
| WO2025075711A1 (en) | Methods and materials for treating hyperoxalemia and/or hyperoxaluria |